Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P22695
UPID:
QCR2_HUMAN
Alternative names:
Complex III subunit 2; Core protein II; Ubiquinol-cytochrome-c reductase complex core protein 2
Alternative UPACC:
P22695; B3KSN4; Q9BQ05
Background:
Cytochrome b-c1 complex subunit 2, mitochondrial, also known as Complex III subunit 2, plays a pivotal role in the mitochondrial electron transport chain. This protein is integral to oxidative phosphorylation, facilitating the transfer of electrons from ubiquinol to cytochrome c and contributing to the proton gradient essential for ATP synthesis.
Therapeutic significance:
Linked to Mitochondrial complex III deficiency, nuclear type 5, Cytochrome b-c1 complex subunit 2's dysfunction manifests in a spectrum of clinical symptoms, including encephalopathy and muscle weakness. Understanding its role could pave the way for targeted therapies in mitochondrial disorders.